| Component: (Network and Table) | |
|---|---|
| Network | 001000 - Statement - CONSOLIDATED BALANCE SHEETS (http://accesspharma.com/role/ConsolidatedBalanceSheets) |
| Table | (Implied) |
| Reporting Entity [Axis] | 0000318306 (http://www.sec.gov/CIK) |
| CONSOLIDATED BALANCE SHEETS (Parenthetical) [Abstract] | Period [Axis] | ||
|---|---|---|---|
2011-12-31 | 2010-12-31 | 2009-12-31 | |
CONSOLIDATED BALANCE SHEETS (Parenthetical) [Abstract] | |||
Current assets | |||
Cash and cash equivalents | 2,460,000 | 7,033,000 | 607,000 |
Receivables | 333,000 | 1,018,000 | |
Inventory | 151,000 | 0 | |
Restricted cash | 330,000 | 0 | |
Prepaid expenses and other current assets | 39,000 | 70,000 | |
Total current assets | 3,313,000 | 8,121,000 | |
Property and equipment, net | 51,000 | 32,000 | |
Patents, net | 362,000 | 574,000 | |
Other assets | 59,000 | 44,000 | |
Total assets | 3,785,000 | 8,771,000 | |
LIABILITIES AND STOCKHOLDERS' DEFICIT | |||
Current liabilities | |||
Accounts payable | 1,713,000 | 2,984,000 | |
Accrued expenses | 857,000 | 857,000 | |
Dividends payable | 6,487,000 | 4,443,000 | |
Accrued interest payable | 98,000 | 126,000 | |
Debt, current portion | 2,750,000 | 5,500,000 | |
Current portion of deferred revenue | 285,000 | 347,000 | |
Total current liabilities | 12,190,000 | 14,257,000 | |
Derivative liability - warrants | 1,507,000 | 5,087,000 | |
Derivative liability - preferred stock | 4,430,000 | 5,840,000 | |
Long-term deferred revenue | 3,264,000 | 4,382,000 | |
Total liabilities | 21,391,000 | 29,566,000 | |
Commitments and contingencies | xsi:nil | xsi:nil | |
Stockholders' deficit | |||
Convertible preferred stock - $.01 par value; authorized 2,000,000 shares; 2,938.3617 issued at December 31, 2011; 2,978.3617 issued at December 31, 2010 | 0 | 0 | |
Common stock - $.01 par value; authorized 100,000,000 shares; issued 23,890,787 at December 31, 2011; issued 19,115,010 at December 31, 2010 | 239,000 | 191,000 | |
Additional paid-in capital | 237,600,000 | 230,153,000 | |
Treasury stock, at cost - 163 shares | (4,000) | (4,000) | |
Accumulated deficit | (255,441,000) | (251,135,000) | |
Total stockholders' deficit | (17,606,000) | (20,795,000) | |
Total liabilities and stockholders' deficit | 3,785,000 | 8,771,000 | |